dismiss

Come visit us at Booth 901 at AHRMM in Washington, DC
Mark your calendars! On August 2nd is our upcoming LIVE Clean Sweep Auction

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Cardiology Homepage

GE Healthcare unveils Productivity Elevated release of cardiac ultrasound system A 'major upgrade' of its cSound diagnostic suite

GE Healthcare and HeartFlow collaborate against coronary artery disease Combining GE CT systems with HeartFlow's FFRct Analysis system

Handheld scanner for diagnosing heart disease under development in EU Could drastically reduce the cost for standard approaches

Researchers develop new method for 3-D printing custom heart valve models May help plan surgery and avoid complications

GE partners with LifeWatch to offer cloud-based ECG monitoring services Triages normal and abnormal ECGs, using algorithms

Philips to acquire cardiac device company Spectranetics for €1.9 billion Will be part of its Image-Guided Therapy Business Group

Philips gets FDA nod to market IntelliSpace Portal 9.0 and new applications Helps quantify and quickly diagnose conditions

Heart disease second leading cause of death for cancer survivors 'It seems cancer and heart disease coexist in a race to kill cancer survivors'

Drone-based defibrillators could make lifesaving difference: study Swedish researchers take lifesaving cardiac devices to the sky

Researchers use ultrasound to break down deep vein blood clots Ninety percent of the clot can be dissolved in four hours

Courtesy of Piramal Imaging GmbH

German researchers develop new PET tracer for detecting blood clots

by Lauren Dubinsky , Senior Reporter
Since anticoagulants for treating for blood clots have the potential to cause life-threatening excessive bleeding, clinicians must weigh the risk of bleeding against the risk of clotting in each patient.

In the future, a new fluorine-18 labeled PET tracer, developed in Germany, may help them make these important decisions. This novel discovery is the topic of a featured article in this month’s issue of The Journal of Nuclear Medicine.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Although the current studies are preliminary, 18F-GP1 may provide not only more accurate anatomic localization, but also information of the risk of the clot growth or embolization,” Dr. Andrew W. Stephens of Piramal Imaging told HCB News. “This may lead to changes in clinical intervention to the individual patient.”

18F-GP1 targets the key receptor involved in platelet clumping, which is known as GPIIb/IIIa. The standard imaging modalities for detecting blood clots such as CT and ultrasound rely on structural characteristics, but the new PET tracer provides physiological information.

“Currently available diagnostic techniques of thrombus imaging rely on different modalities, depending on the vascular territory,” said Stephens. “[They] detect anatomic abnormalities, in this case vascular occlusions, and provide little information on the biological processes ongoing at the level of the occlusion.”

In a preclinical study involving monkeys, the team found that 18F-GP1 strongly accumulates at the site of the thrombus formation, and that its binding ability was not impaired by the anticoagulants. The tracer showed rapid blood clearance, and PET imaging detected small venous and arterial clots, endothelial damage and emboli in the brain.

Because of these positive findings, a clinical study investigating 18F-GP1 is currently underway. First results from an interim analysis are promising and were presented last month at the SNMMI annual meeting.

“The currently available clinical data are preliminary and more research is necessary to better understand the full potential of this compound,” said Stephens.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED